S1.
Patient flow in the study. ALK, anaplastic lymphoma kinase; ARMS, amplification refractory mutation system; RECIST, Response Evaluation Criteria in Solid Tumors; PD, progressive disease; CBPD, crizotinib beyond progressive disease.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.